Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
James J. Harding(Memorial Sloan Kettering Cancer Center)
Cited by 157
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|243
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer
|JCO Precision Oncology|2025|3